MedTrace Logo

Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease

NCT04327752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-07-21

No results posted yet for this study

Summary

Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition. Limited data are available in children treated by BT on cutaneous paradoxical reactions, or any other cutaneous adverse events occurring during treatment. On the contrary, dermatologists tend to see and manage increasing numbers of cutaneous adverse events, including paradoxical reactions. The aim of this project is to describe the incidence of cutaneous adverse events, including cutaneous paradoxical reactions, occurring in the pediatric population, during a treatment by BT given for a chronic inflammatory disease.

Conditions

  • Biotherapy
  • Chronic Inflammatory Disease
  • Allergic Skin Reaction
  • Pediatric Disorder
  • Dermatologic Complication
  • Gastrointestinal Disease
  • Ophthalmology
  • Rheumatology

Interventions

OTHER

dermatological consultation

Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2020-07-01
Completion
2020-10-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327752 on ClinicalTrials.gov